A NEW cancer drug, which could offer hope to hundreds of patients each year suffering from a range of cancers – pancreatic, colon and stomach – is being developed by Singapore researchers; and it has entered clinical trials here.
Developed by the Experimental Therapeutic Centre (ETC) and Drug Discovery and Development (D3) units at the Agency for Science, Technology and Research (A*Star), and Duke-NUS Graduate Medical School, the drug homes in on proteins that cause excessive cell growth when they go rogue, leading to cancers.